Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

BACKGROUND: The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. METHODS: The...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Med
Auteurs principaux: Dieci, Maria Vittoria, Bisagni, Giancarlo, Brandes, Alba A., Frassoldati, Antonio, Cavanna, Luigi, Giotta, Francesco, Aieta, Michele, Gebbia, Vittorio, Musolino, Antonino, Garrone, Ornella, Donadio, Michela, Rimanti, Anita, Beano, Alessandra, Zamagni, Claudio, Soto Parra, Hector, Piacentini, Federico, Danese, Saverio, Ferro, Antonella, Cagossi, Katia, Sarti, Samanta, Gambaro, Anna Rita, Romito, Sante, Bazan, Viviana, Amaducci, Laura, Moretti, Gabriella, Foschini, Maria Pia, Balduzzi, Sara, Vicini, Roberto, D’Amico, Roberto, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6868696/
https://ncbi.nlm.nih.gov/pubmed/31747948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-019-1445-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires